Original Article

You have full text access to this OnlineOpen article

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer†

Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study

  1. Nadine A. Jackson MD, MPH1,
  2. José Barrueco PhD2,
  3. Raoudha Soufi-Mahjoubi MD2,
  4. John Marshall MD3,
  5. Edith Mitchell MD4,
  6. Xiaoxi Zhang PhD2,
  7. Jeffrey Meyerhardt MD, MPH1,‡,*

Article first published online: 20 APR 2009

DOI: 10.1002/cncr.24305

Issue

Cancer

Cancer

Volume 115, Issue 12, pages 2617–2629, 15 June 2009

Additional Information

How to Cite

Jackson, N. A., Barrueco, J., Soufi-Mahjoubi, R., Marshall, J., Mitchell, E., Zhang, X. and Meyerhardt, J. (2009), Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer, 115: 2617–2629. doi: 10.1002/cncr.24305

Author Information

  1. 1

    Department of Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

  2. 2

    Pfizer Global Pharmaceuticals, New York, New York

  3. 3

    Department of Medical Oncology, Georgetown University Lombardi Cancer Center, Washington, District of Columbia

  4. 4

    Department of Medical Oncology, Jefferson Medical College, Philadelphia, Pennsylvania

  1. ‡

    Fax: (617) 632-5370

*44 Binney Street, Boston, MA 02115

  1. †

    Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 1-5, 2007.

Publication History

  1. Issue published online: 4 JUN 2009
  2. Article first published online: 20 APR 2009
  3. Manuscript Accepted: 8 DEC 2008
  4. Manuscript Revised: 19 NOV 2008
  5. Manuscript Received: 10 SEP 2008

Funded by

  • Pfizer Inc, New York

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (344K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M. R. Rutledge, Dominic A. Solimando, J. Aubrey Waddell, Cancer Chemotherapy Update - CapIri (XelIri) Regimen for Advanced and Metastatic Colorectal or Esophogastric Cancer, Hospital Pharmacy, 2012, 47, 2, 98

    CrossRef

  2. 2
    Jose J. G. Marin, Fermin Sanchez de Medina, Beatriz Castaño, Luis Bujanda, Marta R. Romero, Olga Martinez-Augustin, Rosario Del Moral-Avila, Oscar Briz, Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer, Drug Metabolism Reviews, 2012, 44, 2, 148

    CrossRef

  3. 3
    Fausto Petrelli, Mary Cabiddu, Sandro Barni, 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials, Medical Oncology, 2011, 29, 2, 1020

    CrossRef

  4. 4
    Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Naoki Sasahira, Takeshi Tsujino, Hirofumi Kogure, Hiroshi Yagioka, Yoko Yashima, Osama Togawa, Toshihiko Arizumi, Saburo Matsubara, Kenji Hirano, Minoru Tada, Masao Omata, Kazuhiko Koike, Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy, Critical Reviews in Oncology/Hematology, 2011, 78, 3, 252

    CrossRef

  5. 5
    Marianne Fonck, Réné Brunet, Yves Becouarn, Jean-Louis Legoux, Jérôme Dauba, Laurent Cany, Denis Smith, Dominique Auby, Éric Terrebonne, Laurent Traissac, Cécile Mertens, Pierre Soubeyran, Carine Bellera, Muriel Rainfray, Simone Mathoulin-Pélissier, Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: A first-line phase II study, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 12, 823

    CrossRef

  6. 6
    Maria Di Bartolomeo, Filippo Pietrantonio, Antonia Martinetti, Roberto Buzzoni, Arpine Gevorgyan, Emilio Bajetta, Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer, Drugs & Aging, 2011, 28, 2, 83

    CrossRef

  7. 7
    Rafał Stec, Lubomir Bodnar, Cezary Szczylik, Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis, Journal of Cancer Research and Clinical Oncology, 2009, 136, 2, 283

    CrossRef

View Full Article (HTML) Get PDF (344K)